XJPX
4109
Market cap436mUSD
Jul 10, Last price
5,770.00JPY
1D
-0.69%
1Q
13.81%
Jan 2017
84.64%
Name
Stella Chemifa Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Stella Chemifa Corporation, a Japanese company established in 1916 and headquartered in Osaka, specializes as a global manufacturer and supplier of inorganic fluorine compounds. Formerly known as Hashimoto Chemical Corporation until its rebranding in 1997, the company offers a comprehensive product portfolio tailored for diverse industrial applications worldwide. For the electronics sector, Stella Chemifa provides essential materials such as hydrofluoric acid, buffered hydrofluoric acid, and various etching solutions used in the production of semiconductors, liquid crystal displays, and solar cells. It also supplies a range of metal fluorides, including calcium, aluminum, and lithium fluoride, crucial for optical applications, alongside lithium hexafluorophosphate for battery manufacturing. Its offerings extend to numerous boron trifluoride compounds, serving as vital reactive catalysts across different chemical processes. Additionally, the company produces anhydrous hydrofluoric acid and 55% hydrofluoric acid, utilized in surface treatment and as more environmentally conscious alternatives to CFCs. Stella Chemifa also supports the nuclear energy industry with potassium fluoroborate and boric acid, and provides tin fluoride (II) USP for products requiring GMP compliance. Beyond these specialized compounds, the company's extensive catalog includes a broad array of other fluorochemicals, such as fluorosilicic acid, various fluorosilicates, fluoroboric acid, diverse fluoroborates, and a selection of ammonium, sodium, and potassium fluorides. Complementing its manufacturing operations, Stella Chemifa offers logistics services for the transportation of specialized chemical substances, high-pressure gases, and hazardous materials. Demonstrating a commitment to innovation, the company is also actively involved in the development of Boron Neutron Capture therapy for cancer treatment.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||